ArticleInternational journal of nanomedicine2012
Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment.Theranostics · 2025Review
- Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives.Journal of nanobiotechnology · 2023Review
- What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review.Advanced pharmaceutical bulletin · 2023Review
- Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.Frontiers in immunology · 2021Review
- Article
- Dendrimer-Based Drug Delivery Systems for Brain Targeting.Biomolecules · 2019Review
- Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins.Pharmaceutics · 2019Review
- Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells.Drug development research · 2018Article
- Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.Oncology letters · 2018Article
- Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma.Molecular medicine reports · 2018Article
- TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors.Drug delivery · 2017Article
- Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.International journal of nanomedicine · 2017Article
- Onto better TRAILs for cancer treatment.Cell death and differentiation · 2016Review
- Role of nanotechnology and gene delivery systems in TRAIL-based therapies.Ecancermedicalscience · 2016Review
- Advances in Anticancer Protein Delivery Using Micro-/ Nanoparticles.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2014Article
- Houttuynia cordata Thunb extract modulates G0/G1 arrest and Fas/CD95-mediated death receptor apoptotic cell death in human lung cancer A549 cells.Journal of biomedical science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intractability of non-small cell lung cancer (NSCLC) to multimodality treatments plays a large part in its extremely poor prognosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cytokine for selective induction of apoptosis in cancer cells; however, many NSCLC cell lines are resistant to TRAIL-induced apoptosis. The therapeutic effect can be restored by treatments combining TRAIL with chemotherapeutic agents. Actinomycin D (ActD) can sensitize NSCLC cells to TRAIL-induced apoptosis by upregulation of death receptor 4 (DR4) or 5 (DR5). However, the use of ActD has significant drawbacks due to the side effects that result from its nonspecific biodistribution in vivo. In addition, the short half-life of TRAIL in serum also limits the antitumor effect of treatments combining TRAIL and ActD. In this study, we designed a combination treatment of long-circulating TRAIL liposomes and ActD liposomes with the aim of resolving these problems. The combination of TRAIL liposomes and ActD liposomes had a synergistic cytotoxic effect against A-549 cells. The mechanism behind this combination treatment includes both increased expression of DR5 and caspase activation. Moreover, systemic administration of the combination of TRAIL liposomes and ActD liposomes suppressed both tumor formation and growth of established subcutaneous NSCLC xenografts in nude mice, inducing apoptosis without causing significant general toxicity. These results provide preclinical proof-of-principle for a novel therapeutic strategy in which TRAIL liposomes are safely combined with ActD liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.